Pharmacological Prevention of Recurrent Stones

Recurrent nephrolithiasis is a common and challenging condition, with nearly half of affected individuals developing new stones within ten years. Pharmacological prevention, guided by metabolic evaluation and analysis of stone composition, is central to reducing recurrence risk. Thiazide diuretics are widely used in patients with hypercalciuria, as they lower urinary calcium excretion and thereby reduce calcium stone formation. Potassium citrate is effective in correcting hypocitraturia and alkalinizing urine, which prevents calcium oxalate and uric acid stones. Allopurinol, by inhibiting uric acid synthesis, is beneficial in patients with hyperuricosuria or uric acid stones. Other agents, such as magnesium supplements and acetohydroxamic acid, have limited or specialized roles, particularly in struvite stones.

Evidence from randomized controlled trials demonstrates that tailored pharmacological therapy, when combined with lifestyle measures such as adequate hydration, sodium restriction, and moderated protein intake, can reduce recurrence rates by 40–60%. Despite proven efficacy, long-term adherence and monitoring for adverse effects are essential to ensure sustained benefit. Thus, individualized pharmacological intervention, integrated with dietary and behavioral strategies, represents the cornerstone of recurrent stone prevention and remains a critical component of comprehensive management in patients at risk of recurrence.